{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:02Z","timestamp":1784822582429,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00951-x","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:02:22Z","timestamp":1780128142000},"page":"1881-1902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-9643","authenticated-orcid":false,"given":"Enrique","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-4283","authenticated-orcid":false,"given":"Robert T.","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0535-3978","authenticated-orcid":false,"given":"Le H.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-6808","authenticated-orcid":false,"given":"Elmor D.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-2612","authenticated-orcid":false,"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-0812","authenticated-orcid":false,"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohira","family":"L\u00e9vesque-Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-8138","authenticated-orcid":false,"given":"Kunio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-9148","authenticated-orcid":false,"given":"Daniel","family":"Ontaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"2","key":"951_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120.","journal-title":"Mult Scler"},{"key":"951_CR2","unstructured":"Multiple Sclerosis International Federation. Atlas of MS. https:\/\/atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms. Accessed 20 Nov 2025."},{"issue":"3","key":"951_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"4","key":"951_CR4","first-page":"318","volume":"10","author":"LC Politte","year":"2008","unstructured":"Politte LC, Huffman JC, Stern TA. Neuropsychiatric manifestations of multiple sclerosis. Prim Care Companion J Clin Psychiatry. 2008;10(4):318\u201324.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"6","key":"951_CR5","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","volume":"271","author":"BA Singer","year":"2024","unstructured":"Singer BA, Feng J, Chiong-Rivero H. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. J Neurol. 2024;271(6):3116\u201330.","journal-title":"J Neurol"},{"issue":"10","key":"951_CR6","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394.","journal-title":"J Neurol"},{"issue":"12","key":"951_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285\u201399.","journal-title":"CNS Drugs"},{"issue":"7","key":"951_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","volume":"23","author":"A Simpson","year":"2021","unstructured":"Simpson A, Mowry EM, Newsome SD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23(7):19.","journal-title":"Curr Treat Options Neurol"},{"issue":"17","key":"951_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"issue":"1","key":"951_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ncl.2023.06.004","volume":"42","author":"N Bou Rjeily","year":"2024","unstructured":"Bou Rjeily N, Mowry EM, Ontaneda D, Carlson AK. Highly effective therapy versus escalation approaches in early multiple sclerosis: what is the future of multiple sclerosis treatment? Neurol Clin. 2024;42(1):185\u2013201.","journal-title":"Neurol Clin"},{"issue":"5","key":"951_CR11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40120-023-00523-3","volume":"12","author":"CK Geiger","year":"2023","unstructured":"Geiger CK, Sheinson D, To TM, Jones D, Bonine NG. Real-world clinical and economic outcomes among persons with multiple sclerosis initiating first- versus second- or later-line treatment with ocrelizumab. Neurol Ther. 2023;12(5):1709\u201328.","journal-title":"Neurol Ther"},{"key":"951_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.693017","volume":"12","author":"CS Simonsen","year":"2021","unstructured":"Simonsen CS, Flemmen H, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2\u00a0years in a Norwegian population-based registry. Front Neurol. 2021;12:693017.","journal-title":"Front Neurol"},{"issue":"1","key":"951_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol. 2024;271(1):105\u201315.","journal-title":"J Neurol"},{"key":"951_CR14","unstructured":"Genentech, Inc. Ocrevus (ocrelizumab) prescribing information. 2020. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. Accessed 20 Nov 2025."},{"key":"951_CR15","unstructured":"Roche Pharma AG. Ocrevus (ocrelizumab) summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf. Accessed 20 Nov 2025."},{"key":"951_CR16","unstructured":"Hauser S, Giovannoni G, Filippi M, et al. The patient impact of 11\u00a0years of ocrelizumab\u00a0treatment in multiple sclerosis: long-term data\u00a0from the phase\u00a0III OPERA and ORATORIO studies (P1664). European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Copenhagen, Denmark 2024."},{"issue":"4","key":"951_CR17","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/ene.14823","volume":"29","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Kappos L, de Seze J, et al. Risk of requiring a walking aid after 6.5\u00a0years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA\u00a0I and OPERA\u00a0II trials. Eur J Neurol. 2022;29(4):1238\u201342.","journal-title":"Eur J Neurol"},{"issue":"3","key":"951_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"12","key":"951_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2020;19(12):998\u20131009.","journal-title":"Lancet Neurol"},{"key":"951_CR20","doi-asserted-by":"crossref","unstructured":"Hauser S, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: up to 11\u00a0years of updated analysis in patients with relapsing and progressive multiple sclerosis\u00a0(P300). European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Copenhagen, Denmark 2024.","DOI":"10.1016\/j.msard.2023.105308"},{"key":"951_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101525","volume":"38","author":"LE Baldassari","year":"2020","unstructured":"Baldassari LE, Nakamura K, Moss BP, et al. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Mult Scler Relat Disord. 2020;38:101525.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"951_CR22","volume":"5","author":"J Feng","year":"2019","unstructured":"Feng J, Offerman E, Lin J, et al. Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler J. 2019;5(2):2055217319856035.","journal-title":"Mult Scler J"},{"key":"951_CR23","doi-asserted-by":"publisher","first-page":"102707","DOI":"10.1016\/j.nicl.2021.102707","volume":"31","author":"M Raki\u0107","year":"2021","unstructured":"Raki\u0107 M, Vercruyssen S, Van Eyndhoven S, et al. icobrain ms 5.1: combining unsupervised and supervised approaches for improving the detection of multiple sclerosis lesions. Neuroimage Clin. 2021;31:102707.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"951_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61798-6","volume":"14","author":"J Simarro","year":"2024","unstructured":"Simarro J, Meyer MI, Van Eyndhoven S, et al. A deep learning model for brain segmentation across pediatric and adult populations. Sci Rep. 2024;14(1):11735.","journal-title":"Sci Rep"},{"key":"951_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-37","volume":"13","author":"YC Learmonth","year":"2013","unstructured":"Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of Patient Determined Disease Steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013;13:37-2377-13-37.","journal-title":"BMC Neurol"},{"issue":"1","key":"951_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7224\/1537-2073.2021-102","volume":"25","author":"RA Marrie","year":"2023","unstructured":"Marrie RA, McFadyen C, Yaeger L, Salter A. A systematic review of the validity and reliability of the Patient-Determined Disease Steps Scale. Int J MS Care. 2023;25(1):20\u20135.","journal-title":"Int J MS Care"},{"key":"951_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104794","volume":"76","author":"MJ Williams","year":"2023","unstructured":"Williams MJ, Okai AF, Cross AH, et al. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase\u00a0IV CHIMES trial. Mult Scler Relat Disord. 2023;76:104794.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"951_CR28","first-page":"1211","volume":"30","author":"ECS Swart","year":"2024","unstructured":"Swart ECS, Peasah SK, Alderson J, Maxwell R, Manolis C, Good CB. Patient-reported disability progression outcomes among patients with multiple sclerosis: results of an outcomes-based agreement. J Manag Care Spec Pharm. 2024;30(11):1211\u20136.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"951_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/pan\/mpr025","volume":"20","author":"J Hainmueller","year":"2012","unstructured":"Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25\u201346. https:\/\/doi.org\/10.1093\/pan\/mpr025.","journal-title":"Polit Anal"},{"issue":"12","key":"951_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210049","volume":"103","author":"HP Hartung","year":"2024","unstructured":"Hartung HP, Benedict RHB, Berger T, et al. Ocrelizumab in early-stage relapsing-remitting multiple sclerosis: the phase\u00a0IIIb ENSEMBLE 4-year, single-arm, open-label trial. Neurology. 2024;103(12):e210049.","journal-title":"Neurology"},{"issue":"5","key":"951_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536\u201341.","journal-title":"JAMA Neurol"},{"issue":"8","key":"951_CR32","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","volume":"95","author":"MD Buron","year":"2020","unstructured":"Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95(8):e1041\u201351.","journal-title":"Neurology"},{"issue":"10","key":"951_CR33","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197\u2013204.","journal-title":"JAMA Neurol"},{"issue":"2","key":"951_CR34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00415-021-10673-9","volume":"269","author":"K H\u00e4nninen","year":"2022","unstructured":"H\u00e4nninen K, Viitala M, Atula S, Laakso SM, Kuusisto H, Soilu-H\u00e4nninen M. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. J Neurol. 2022;269(2):913\u201322.","journal-title":"J Neurol"},{"issue":"2","key":"951_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175\u201387.","journal-title":"JAMA"},{"issue":"4","key":"951_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316.","journal-title":"Lancet Neurol"},{"key":"951_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103860","volume":"63","author":"MZ Kozlicki","year":"2022","unstructured":"Kozlicki MZ, Markley B, Shah NB, DeClercq J, Choi L, Zuckerman AD. A cross-sectional analysis of persistence to disease-modifying therapies in treatment na\u00efve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy. Mult Scler Relat Disord. 2022;63:103860.","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00951-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:27Z","timestamp":1784819487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00951-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00951-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Enrique Alvarez has received compensation for activities such as advisory boards, lectures, and consultancy from Alexion, Biogen, Celgene\/Bristol Myers Squibb, Cionic, EMD Serono\/Merck, Genentech, Inc.\/F. Hoffmann-La Roche Ltd, Horizon, Novartis, Sanofi, and TG Therapeutics and research support from Biogen, Genentech, Inc.\/F. Hoffmann-La Roche Ltd, Novartis, National Institutes of Health, National Multiple Sclerosis Society, Patient-Centered Outcomes Research Institute, Rocky Mountain MS Center, and TG Therapeutics. Le H. Hua has received personal compensation for speaking, consulting, and\/or advisory board activities from Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Inc., Genzyme, Horizon, Novartis, and TG Therapeutics, and has received research support paid to their institution from Genentech, Inc. Robert T. Naismith has consulted for Alexion, Biogen, Bristol Myers Squibb, Celltrion, EMD Serono, Genentech, Inc., Genzyme, Horizon, Novartis, and TG Therapeutics. Elmor D. Pineda is an employee of Genentech, Inc., and shareholder of F. Hoffmann-La Roche Ltd. Hela Romdhani, Annie Gu\u00e9rin and Mohira L\u00e9vesque-Leroux are employees of Analysis Group, ULC, a consulting company that received funding from Genentech, Inc. Gayatri Marathe was an employee of the Analysis Group, ULC, at the time of the study and is currently an employee of Alexion Pharmaceuticals, Inc. Kunio Nakamura received research support from Biogen, Bristol Myers Squibb, National Multiple Sclerosis Society, Patient-Centered Outcomes Research Institute, Synaptogenix, US Department of Defense, and US National Institutes of Health. Daniel Ontaneda received research support from Bristol Myers Squibb, Genentech, Inc., Genzyme, National Institutes of Health, National Multiple Sclerosis Society, Novartis, Patient-Centered Outcomes Research Institute, and Race to Erase MS Foundation, and consulting fees from Biogen, Bristol Myers Squibb, Genentech, Inc.\/F. Hoffmann-La Roche Ltd, Genzyme, Novartis, Pipeline Therapeutics, Convelo, and Sanofi.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anonymized patient data were collected from participating clinical sites following institutional review board approval at each site and in accordance with the Helsinki Declaration of 1964 and its later amendments. The study was approved by the Cleveland Clinic Institutional Review Board (23-1329), the Colorado Multiple Institutional Review Board (23-0339), and the Washington University in St.\u00a0Louis Institutional Review Board (202308182). The study was determined to be minimal risk as a result of using secondary data\/data collected for routine clinical practice; therefore, informed consent and HIPAA authorization were waived.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}